F S&P 500
5,118.25 +11.75 (+0.23%) F Dow Jones
38,739.00 +13.00 (+0.03%) F Nasdaq
17,708.75 +102.00 (+0.58%) E-mini Russell 2000 Index Futur
2,017.00 +2.10 (+0.10%) Petróleo
83.45 +0.09 (+0.11%) Oro
2,336.40 -5.70 (-0.24%)
Pacira BioSciences, Inc. (PCRX)
Fuera de horario:
Pacira BioSciences, Inc.
5401 West Kennedy Boulevard
Suite 890
Tampa, FL 33609
United States
813 553 6680
https://www.pacira.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 711
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Charles A. Reinhart III, CPA, M.B.A. | Chief Financial Officer | 780.58k | N/D | 1961 |
| Mr. Daryl Gaugler | Chief Operating Officer | 778.77k | 115k | 1962 |
| Ms. Kristen Williams J.D. | Chief Administrative Officer & Secretary | 799.63k | 857.7k | 1974 |
| Mr. Anthony Molloy III, Esq. | Chief Legal & Compliance Officer | 581.41k | 802.07k | 1974 |
| Mr. David M. Stack | Advisor | 1.54M | 4.37M | 1950 |
| Mr. Frank D. Lee | CEO & Director | N/D | N/D | 1968 |
| Ms. Lauren Bullaro Riker | Principal Accounting Officer & Senior VP of Finance | 288.81k | 196.6k | 1979 |
| Susan Mesco | Head of Investor Relations | N/D | N/D | N/D |
| Mr. Richard Kahr | Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Jonathan Slonin M.D. | Chief Medical Officer | 815.25k | N/D | 1976 |
Descripción
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Gestión corporativa
La calificación ISS Governance QuickScore de Pacira BioSciences, Inc. a partir del 1 de abril de 2024 es 4. Las puntuaciones principales son Auditoría: 1; Junta: 3; Derechos del accionista: 7; Compensación: 6.
